8-KLeadership Changes

BECTON DICKINSON & CO 8-K Report, Executive Changes (Jul 24, 2023)

Filed July 24, 2023For Securities:BDX

Summary

Becton, Dickinson and Company (BDX) has announced a significant change to its Board of Directors with the election of Dr. Joanne Waldstreicher, effective July 24, 2023. Dr. Waldstreicher's appointment brings additional expertise to the board and is expected to contribute to key committees, specifically the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee. Her addition is a strategic move to enhance board oversight in critical areas of the company's operations and governance. Investors should note that Dr. Waldstreicher has been deemed independent according to NYSE and BD's own governance standards, which is a positive indicator for objective oversight. Her compensation for board service includes restricted stock units valued at $107,795, prorated for her tenure. This compensation structure aligns her interests with those of shareholders through equity ownership, a common practice to incentivize long-term performance and shareholder value.

Key Highlights

  • 1Dr. Joanne Waldstreicher elected to Becton, Dickinson and Company's (BDX) Board of Directors, effective July 24, 2023.
  • 2Dr. Waldstreicher will serve on the Corporate Governance and Nominating Committee.
  • 3Dr. Waldstreicher will also serve on the Quality and Regulatory Committee.
  • 4BDX Board has determined Dr. Waldstreicher is independent under NYSE and BD's governance guidelines.
  • 5Dr. Waldstreicher will receive restricted stock units valued at $107,795 as compensation.
  • 6The restricted stock unit grant is prorated based on her service period until the 2024 Annual Meeting of Shareholders.

Frequently Asked Questions

Dr. Joanne Waldstreicher has been elected to BDX's Board of Directors. Her appointment is significant as it brings new expertise to the board and strengthens oversight in critical areas like corporate governance and quality/regulatory matters through her committee assignments.

Yes, the BDX Board of Directors has determined that Dr. Waldstreicher meets the independence requirements under the rules of the New York Stock Exchange and BD's own Statement of Corporate Governance Principles.

Dr. Waldstreicher will receive restricted stock units valued at $107,795. This compensation is prorated from her election date until the 2024 Annual Meeting of Shareholders, aligning her interests with long-term shareholder value.

Dr. Waldstreicher will be a member of two key committees: the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee.